Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004–2014

Marco, Francesc; Dowzicky, M.

doi:10.1016/j.jgar.2016.02.005

Cited by 12 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We report that 90% of A. baumannii isolates were inhibited by tigecycline at a concentration of 2 mg/L. This is comparable with reports from Italy [26], Eastern Europe [27] and Spain [28]. …”

Section: Discussionsupporting

confidence: 88%

“…As with other studies, both from Italy and other European countries, linezolid, tigecycline and vancomycin were the most active agents against S. aureus , including MRSA [7,17,27,28]. There were no MRSA or enterococci isolates that were resistant to linezolid despite other European reports showing outbreaks of linezolid-resistant MRSA and linezolid-resistant enterococci [17,29,30,31].…”

Section: Discussionsupporting

confidence: 68%

See 1 more Smart Citation

Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

Stefani

Dowzicky

2016

Pharmaceuticals

View full text Add to dashboard Cite

As part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T) we report the in vitro activity of tigecycline and its comparators against Gram-negative and Gram-positive organisms collected from Italian centers between 2012 and 2014. Minimum inhibitory concentrations were determined according to the broth microdilution methodology of the Clinical and Laboratory Standards Institute, and antimicrobial resistance was determined using the European Committee on Antimicrobial Susceptibility Testing interpretive criteria. Among the Enterobacteriaceae, 31% of Escherichia coli isolates, 22% of Klebsiella pneumoniae, and 1% of Klebsiella oxytoca were extended-spectrum β-lactamase producers (ESBLs). Resistance rates among ESBL-K. pneumoniae and ESBL-E. coli to meropenem were 24% and <1%, respectively. Thirty-seven percent of K. pneumoniae were multidrug resistant (MDR) strains. Resistance rates among isolates of Acinetobacter baumannii to amikacin, levofloxacin and meropenem were between 84% and 94%. Eighty percent of A. baumannii isolates were MDR strains. Methicillin-resistant Staphylococcus aureus (MRSA) accounted for 38% of S. aureus isolates. No isolates of MRSA were resistant to linezolid, tigecycline or vancomycin. Antimicrobial resistance remains a problem in Italy with increasing numbers of MDR organisms. Despite high levels, MRSA rates appear to be stabilising. Tigecycline retains its in vitro activity against the majority of organisms, including those with multidrug resistance.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 68%

Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

Stefani

Dowzicky

2016

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…A ten-year study in Spain (from 2004–2014) demonstrated that the percentage of antibiotic-resistant strains of A. baumannii to groups I (40%), IV (73.6%) and VIII (58.4%) was similar to the percentage observed in Taiwan 23 . Studies conducted in Saudi Arabia and Greece in 2014 indicated extremely high percentages of antibiotic-resistant bacteria (>89%) to quinolone, beta-lactam/beta-lactamase inhibitor, cephalosporin and carbapenem antibiotics 24, 25 .…”

Section: Discussionmentioning

confidence: 69%

Clinical Antibiotic-resistant Acinetobacter baumannii Strains with Higher Susceptibility to Environmental Phages than Antibiotic-sensitive Strains

Chen

Kuo

Chang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Antibiotic-resistant Acinetobacter baumannii is associated with nosocomial infections worldwide. Here, we used clinically isolated A. baumannii strains as models to demonstrate whether antibiotic resistance is correlated with an increased susceptibility to bacteriophages. In this study, 24 active phages capable of infecting A. baumannii were isolated from various environments, and the susceptibilities of both antibiotic-sensitive and antibiotic-resistant strains of A. baumannii to different phages were compared. In our study, a total of 403 clinically isolated A. baumannii strains were identified. On average, the phage infection percentage of the antibiotic-resistant A. baumannii strains was 84% (from 81–86%), whereas the infection percentage in the antibiotic-sensitive A. baumannii strains was only 56.5% (from 49–64%). In addition, the risk of phage infection for A. baumannii was significantly increased in the strains that were resistant to at least four antibiotics and exhibited a dose-dependent response (p-trend < 0.0001). Among all of the A. baumannii isolates, 75.6% were phage typeable. The results of phage typing might also reveal the antibiotic-resistant profiles of clinical A. baumannii strains. In conclusion, phage susceptibility represents an evolutionary trade-off in A. baumannii strains that show adaptations for antibiotic resistance, particularly in medical environments that have high antibiotic use.

show abstract

“…ОБЗОР ЛИТЕРАТУРЫ 3 и энтеробактерий, продуцирующих БЛРС, чувстви-тельны к тигециклину [29]. Препарат не активен в отношении P. aeruginosa.…”

Section: тигецик линunclassified

“…и энтеробактерий, продуцирующих карбапенемазы. По данным многоцентрового исследования, проведен-ного в Испании, более 80% штаммов Acinetobacter spp.ОБЗОР ЛИТЕРАТУРЫ 3 и энтеробактерий, продуцирующих БЛРС, чувстви-тельны к тигециклину [29]. Препарат не активен в отношении P. aeruginosa.…”

unclassified

Antibacterial Therapy of Septic Complications in Resistance of Pathogens to Carbapenems

Черненькая¹

2017

Neotložnaâ med. pomoŝʹ

View full text Add to dashboard Cite

ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского Департамента здравоохранения г. Москвы», Москва, Российская Федерация Контактная информация: Татьяна Витальевна Черненькая, кандидат медицинских наук, заведующая научной лабораторией кли-нической микробиологии НИИ СП им. Н.В. Склифосовского ДЗ г. Москвы. Е-mail: chernenkayat@rambler.ru РЕЗЮМЕ В настоящее время устойчивость грамотрицательных бактерий к карбапенемам приобретает глобальные масштабы. В случае развития заболеваний, вызванных такими возбудителями, отме-чается неэффективность стандартных схем антибактериальной терапии. Следствие этого -зна-чительное увеличение длительности госпитализации, затрат на лечение и летальности. В обзоре литературы представлены возможности антибактериальной терапии для лечения инфекций, вы-званных резистентными к карбапенемам возбудителями. Ключевые слова:карбапенемы, резистентность, антибиотики, Acinetobacter spp., Pseudomonas aeruginosa, Klebsiella pneumonia.Chernenkaya грамотрицательных бактерий с помощью плазмид. А они в своем составе часто несут детерминанты устой-чивости к антибиотикам разных групп. Так очень быс-тро происходит одномоментная передача фенотипа множественной лекарственной устойчивости [12, 13]. Таким образом, резистентность к карбапенемам можно рассматривать как маркер множественной лекарственной устойчивости бактерий, и, следова-тельно, неэффективности стандартных схем антибак-териальной терапии. В связи с этим представляется актуальным обсуждение имеющихся терапевтических возможностей в лечении инфекций, вызванных резис-тентными к карбапенемам возбудителями. НОВЫЕ АНТИБИОТИКИ В 2009 г. Американское общество инфекционных болезней (Infectious Diseases Society of America -IDSA)анонсировало «инициативу 10х20», в рамках которой к 2020 г. предполагается разработать десять новых антибиотиков [14].В 2014 г. Управлением по надзору за качеством пищевых продуктов и медикаментов США (Food and Drug Administration U.S. -FDA) одобрены четыре антибиотика: далбаванцин (dalbavancin), тедизолид (tedizolid), оритаванцин (oritavancin) и цефтолозан/ тазобактам (ceftolozane/tazobactam) [15]. В 2015 г. был одобрен цефтазидим/авибактам (ceftazidime/avibactam) [16]. Первые три препарата обладают преимуществен-ной активностью против грамположительных возбу-дителей.Спектр активности цефтолозан/тазобактама включает грамотрицательные бактерии, в том числе БЛРС-продуцирующие энтеробактерии и Pseudomonas aeruginosa. Но препарат не ингибирует большинство сериновых карбапенемаз и металлобета-лактамаз, и, следовательно, в случае инфекций, вызванных устой-чивыми к карбапенемам возбудителями, он будет неэффективен [17].Цефтазидим/авибактам -первый цефалоспорин, обладающий активностью в отношении большинства карбапенемаз, за исключением металлобета-лактамаз [18]. В России он пока не зарегистрирован.Еще несколько препаратов с потенциальной актив-ностью против полирезистентных грамотрицательных бактерий в настоящее время находятся на 2-3-й стади-ях клинических испытаний. Но все они принадлежат к уже длительно применяемым классам антибиотиков:-Ами...

show abstract

Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004–2014

Cited by 12 publications

References 25 publications

Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

Clinical Antibiotic-resistant Acinetobacter baumannii Strains with Higher Susceptibility to Environmental Phages than Antibiotic-sensitive Strains

Antibacterial Therapy of Septic Complications in Resistance of Pathogens to Carbapenems

Contact Info

Product

Resources

About